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 For patients with stage V chronic kidney 
disease (CKD), the risk of cardiovascular 
disease is increased as much as tenfold 
beyond that predicted by Framingham risk 
factors. While there are several processes 
associated with this increase, including 
abnormalities in calcium and phosphorous 
metabolism and infl ammation, it is clear 
that lipoprotein metabolism is disordered. 
 Increased low-density lipoprotein 
(LDL) levels are not associated with mor-
tality in this population, but low high-
density lipoprotein (HDL) levels are. 1 
HDL is normally protective, both because 
it effects reverse cholesterol transport, 
stripping cholesterol from endothelial-
bound  macrophages and returning it to 
the liver (Figure 1), and because it serves 
as an anti-infl ammatory and antioxidative 
protein. However, it has been shown pre-
viously that HDL isolated from dialysis 
patients is less eff ective in protecting LDL 
from oxidation as compared with HDL 
obtained from normal individuals, while 
at the same time LDL from dialysis 
patients is more readily oxidized than LDL 
obtained from normal subjects. 2 Although 
LDL cholesterol levels are not a cardiovas-
cular risk factor among dialysis patients, 
the level of oxidized LDL is. HDL levels 
are reduced in patients with CKD, and the 
HDL that is present is dysfunctional. 
 Eff orts to reduce the excessive cardio-
vascular burdens among patients with 
stage V CKD by multiple diff erent strate-
gies — using non-phosphorous calcium 
binders; lowering LDL cholesterol with 
statins in two large randomized clinical 
trials; increasing hemoglobin with eryth-
ropoietic agents; increasing the dose of 
dialysis delivered — have thus far not 
shown benefi t. Vaziri  et al. 3 (this issue) 
used an apolipoprotein (Apo)A-I mimetic 
peptide in an  in vitro system and showed 
that it could reduce the eff ect of oxidized 
LDL on stimulation of cultured aortic 
endothelial cells — even beyond the pro-
tection aff orded by HDL obtained from 
normal subjects — to produce the cytokine 
monocyte chemoattractant protein-1 
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 High-density lipoprotein (HDL) cholesterol level is low in dialysis patients. 
The HDL that is present is dysfunctional, failing to protect low-density 
lipoprotein (LDL) from oxidation and reduce levels of oxidized LDL. Addition 
of the orally absorbable amphipathic peptide 4-F to LDL obtained from 
dialysis patients protects LDL from oxidation  in vitro and reduces the 
capacity of oxidized LDL to induce expression of monocyte chemoattractant 
protein-1 (MCP-1) by vascular endothelial function in culture, potentially 
providing a tool to reduce cardiovascular risk in dialysis patients. 
 Kidney International (2009)  76, 359 – 361.  doi: 10.1038/ki.2009.205 
(MCP-1). Th is could possibly provide a 
pharmacologic substitute for the dysfunc-
tional HDL present in CKD. 
 Decreased HDL cholesterol concentra-
tion is a prominent risk factor for the onset 
of kidney disease, for loss of kidney func-
tion once CKD is present, 4 and for cardio-
vascular disease both among patients with 
CKD and among dialysis patients. 1 
Although fi bric acid derivatives do increase 
HDL cholesterol level, they do not reduce 
the risk of progression of renal failure or 
alter cardiovascular outcome; 5 this sug-
gests that more HDL per se may not resolve 
the eff ects of altered lipoprotein levels in 
these patients and that HDL structure and 
function may also play a role. 
 ApoA-I, the principal apolipoprotein 
contained in HDL, is synthesized and 
secreted by the liver and gut. It then 
engages the adenosine triphosphate – bind-
ing cassette transporter A-1 (ABCA1) — or, 
more specifically, ABCG1, located on 
endothelial-bound macrophages — acquir-
ing cholesterol and initiating reverse cho-
lesterol transport (Figure 1). Th e nascent 
discoid HDL particle, migrating in the 
pre-  -HDL range, is then acted upon by 
lecithin – cholesterol acyltransferase 
(LCAT), which esterifi es cholesterol; this 
allows the more lipophilic cholesterol 
esters to sink into the core, forming spher-
ical   -migrating HDL 3 and, by further 
action of the same enzyme, creating the 
larger, more buoyant HDL 2 . HDL 2 engages 
scavenger receptor B1 and is thus taken up 
by the liver, concluding reverse cholesterol 
transport (Figure 1 ). LCAT activity 
decreases with increasing vintage 6 (years 
on dialysis) in hemodialysis patients and 
recovers aft er kidney transplantation, 7 sug-
gesting that this defect is conferred by kid-
ney failure. A decrease in LCAT reduces 
the rate of HDL maturation, favoring a 
relative increase in both small, dense iso-
forms of HDL, primarily pre-  -HDL, and, 
to a lesser extent, HDL 3 . In healthy indi-
viduals the HDL 3 isoform is a better anti-
oxidant than the larger HDL 2 isoform. 
HDL 3 carries a greater  concentration of 
the antioxidative enzymes paraoxonase 1 
(PON1) and aryl hydrocarbon hydrolase 
and other anti-inflammatory proteins. 
PON1 activity is reduced in patients with 
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properties of ApoA-I. ApoA-I is 243 
amino acids in length and, like other 
apolipoproteins, is highly amphipathic, 
having both hydrophobic and hydrophilic 
domains. Vaziri  et al. 3 show that whereas 
HDL from normal control subjects was 
able to protect LDL from oxidation, HDL 
from dialysis patients was not. LDL from 
dialysis patients stimulated production 
of monocyte chemotactic activity by cul-
tured aortic endothelial cells when com-
pared with control LDL. Th e addition of 
4F reduced this eff ect in the presence or 
absence of HDL from either dialysis 
patients or  normal control subjects. Th e 
fact that 4F has an eff ect superimposed on 
normal HDL suggests that this may be a 
pharmacologic eff ect of the peptide and 
not be directly related to restoration of 
normal HDL function. 
 4F has been shown to be anti-atheroscle-
rotic in experimental animals and also 
shift s ApoA-I from the   -migrating pool to 
the pre-  -migrating pool, potentially 
CKD in part because of accumulation of 
advanced glycation end products and of 
acrolein, contributing to the dysfunction 
of HDL in these patients. 8 
 Neutrophil myeloperoxidase and 
increased oxidative stress, which are prev-
alent during infl ammation and are associ-
ated with renal failure, oxidize LDL. 
During the acute phase response, HDL 
may lose its anti-infl ammatory eff ect and 
actually become a pro-oxidant protein. 9 
Th is is in part due to a reduction in the 
content of antioxidant enzymes carried by 
HDL during the acute phase response, and 
in part because ApoA-I is replaced within 
HDL by an acute phase protein, serum 
amyloid A. Oxidized LDL is an important 
cardiovascular risk factor in its own right 10 
and is increased in dialysis patients. Nor-
mal HDL either prevents or delays LDL 
oxidation or reduces oxidized LDL, 
whereas HDL obtained from dialysis 
patients serves as a poor antioxidant, fail-
ing both to protect LDL from oxidative 
injury and to reduce oxidized LDL. 2 Lipid 
hydroperoxides transfer from oxidized 
LDL to vascular endothelial cells, where 
they induce expression of MCP-1, an 
essential chemokine involved in monocyte 
traffi  c across endothelial and epithelial 
barriers that is responsible for monocyte 
chemotactic activity (Figure 1). 
 Vaziri  et al. 3 now report that addition 
of the ApoA-I mimetic peptide 4F to LDL 
obtained from dialysis patients reduces 
its capacity to increase monocyte chemo-
tactic activity in vascular endothelial cells 
in culture. The term  ‘ ApoA-I mimetic 
protein ’ is somewhat misleading, as the 
protein does not have any sequence 
homology to ApoA-I. Th e protein used, 
4F, is a peptide 18 amino acids in length 
with four phenylalanine residues (single-
letter amino acid code F, hence the name 
4F) and is one of a group of peptides that 
have the capacity to form an amphipathic 
helix, similar to that formed by ApoA-I, 
mimicking many of the lipid-binding 
 Figure 1  |  Maturation of HDL and the protective effect of the ApoA-I mimetic peptide 4F. Apolipoprotein (Apo)A-I is secreted by the liver and gut and 
engages the adenosine triphosphate – binding cassette transporter G-1 protein (ABCG1), taking up cholesterol from macrophages and forming discoidal 
pre-  -migrating HDL. HDL is matured by action of lecithin – cholesterol acyltransferase (LCAT), forming HDL 3 and, ultimately, large buoyant HDL 2 , which is 
then taken up by the liver, engaging scavenger receptor B1 (SR-B1). HDL 3 and, to a lesser extent, HDL 2 are normally rich in antioxidative enzymes, including 
paraoxonase 1 (PON1). Oxidized LDL carries lipid hydroperoxides, binds to vascular endothelium via the lipoprotein-like receptor (LRP), and stimulates 
vascular endothelial cells (VEC) to produce monocyte chemoattractant protein-1 (MCP-1). The amphipathic 18-amino-acid peptide 4F both retrieves lipid 
hydroperoxides from LDL and substitutes for ApoA-I in uptake of cholesterol by engaging ABCG1, protecting endothelial cells from inflammation.  
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 facilitating its interaction with ABCG1 and 
thus allowing increased unloading of cho-
lesterol from lipid-laden macrophages on 
arterial walls. In experimental models, oral 
administration of 4F increased PON1 
activity in the pre-  -HDL fraction, a frac-
tion not normally associated with PON1 
activity, which might explain the protective 
eff ect of this peptide. 4F is less eff ective 
than native ApoA-I in activating LCAT, so 
this specific defect in HDL maturation 
observed in kidney failure is unlikely to be 
reversed by either 4F or other ApoA-I 
mimetic peptides. Th is agent, however, may 
serve as a pharmacologic tool to reverse 
abnormalities in HDL structure that 
accompany renal failure and may perhaps 
serve as a tool to repair vascular injury. 
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 Intrauterine growth retardation, infl u-
enced by the decreased supply of nutrients 
to the human fetus and its environment, 
with resulting low birth weight, was the 
basis of the Brenner hypothesis. This 
hypothesis, which states that low birth 
weight constitutes a risk factor for diseases 
in later life such as systemic arterial hyper-
tension and chronic kidney disease, built 
on the Barker hypothesis, which first 
established a framework for the intrauter-
ine origin of diseases suff ered in adult-
hood. Since the late 1980s and early 1990s, 
when these theories were introduced, 
 signifi cant work has been generated to 
support an inversely related causal link 
between nephron endowment at birth and 
essential hypertension in adult humans, 
supporting the ideas of Barker and Bren-
ner as more than hypotheses. 1 
 For babies born before 36 weeks of 
 gestation, neonatal intensive care units are 
expected to replicate intrauterine develop-
ment. However, many premature infants 
do not demonstrate the expected intrauter-
ine growth at the time of discharge; this has 
resulted in a new term: extrauterine growth 
retardation (EUGR). Clark  et al. defi ne 
EUGR as a growth value  ≤ 10th percentile 
of intrauterine growth expectation based 
on estimated postmenstrual age in prema-
ture neonates (23 – 34 weeks ’ estimated 
gestational age) at the time of discharge 
from the hospital. 2 To date, the notion of 
EUGR as a factor in the development of 
chronic kidney disease or adult-onset sys-
temic arterial hypertension has not been 
fully developed. As nephrogenesis is not 
complete until 36 weeks of  gestation, the 
potential eff ect of EUGR is particularly 
relevant in premature babies. 3 
 In this regard, Bacchetta  et al. 4 (this 
issue) report on the renal function of pre-
mature babies (birth weight   <  1000  g and /
 or   <  30 weeks of gestation) in a 
single-center prospective cohort study. 
Although the authors address measures of 
blood pressure, kidney size, and tubular 
function, as others have done in the past, 
they demonstrate an association between 
EUGR and decreased glomerular fi ltration 
rate (GFR), but within the range of normal 
in childhood. Th ey postulated that this 
moderate decrease in GFR may correspond 
to moderately reduced nephron number, 
which although asymptomatic in child-
hood, may have implications in adulthood. 
Bacchetta  et al. also noted an association 
between decreased protein intake at 7 days 
of life and EUGR in premature babies. 
Their study is novel in that GFR was 
 measured with the use of an exogenous 
marker, inulin, resulting in a more accurate 
assessment of GFR. When prior studies 
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 It ’ s not over till 
the last glomerulus forms 
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 The Brenner hypothesis postulated that low birth weight and decreased 
nephron number at birth are linked to chronic kidney disease and 
systemic hypertension in adulthood. To date, little is known about the 
effect of extrauterine growth retardation (EUGR) on adult kidney 
disease. Bacchetta  et al. present novel data using inulin to show a 
decrease in renal function for premature children with EUGR. The role of 
protein nutrition and timing in nephrogenesis is discussed. 
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